16 results about "Dose drugs" patented technology

Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and / or preventing an immune system disease.

The invention relates to a preparation method and application of a hydrogel microneedle loaded with a glutathione storage cavery.The preparation method aims at achieving more efficient drug delivery, and according to the technical scheme, the preparation method specifically comprises the following steps that 1, a PDMS microneedle female template is prepared; 2) preparing a hydrogel microneedle material solution; 3) preparing a blank hydrogel microneedle; (4) preparing a hydrogel microneedle loaded with a glutathione storage cavern; the hydrogel microneedle loaded with the glutathione reservoir integrates the advantages of the hydrogel microneedle and the drug reservoir, the hydrogel microneedle can form a tiny channel on the skin surface, percutaneous delivery of drugs is promoted, the drug delivery efficiency is improved, the drug reservoir is carried, and the drug delivery efficiency is improved. The hydrogel microneedle has the advantages that glutathione can be prevented from being degraded due to high-temperature crosslinking and the like in the preparation process of the microneedle, the hydrogel microneedle and the glutathione reservoir are jointly applied, limitation of limited space of a microneedle body is broken through, continuous large-dose administration is realized, and the hydrogel microneedle has high percutaneous delivery efficiency.

The invention belongs to the technical field of neurobiology, and particularly relates to application of a dopamine D2 receptor G protein antagonist in preparation of a drug for treating drug addiction. Researches show that the dopamine D2 receptor G protein antagonist can inhibit recurrence after drug addiction fading induced by ignition of small-dose drugs. A mouse cocaine self-administration addiction model is adopted, a small dose of cocaine is given after model mice are subjected to regression training, and the recurrence behavior of the mouse cocaine addiction after regression is induced. A signal channel dependent on dopamine D2 receptor downstream G protein is inhibited before addiction recurrence is induced by a small dose of cocaine, and recurrence after drug-induced cocaine fading can be inhibited; however, the signal pathway for inhibiting the dependence of beta-arretin on the downstream of the dopamine D2 receptor cannot inhibit the recurrence after drug-induced cocaine fading. The invention discloses the effect of the G protein biased antagonist of the dopamine D2 receptor in treatment of drug addiction, and provides a new thought and a drug intervention target for treatment of drug addiction of cocaine and the like.

The invention belongs to the technical field of medicines, and particularly relates to a high-efficiency low-toxicity anticancer combined medicine and a pharmaceutical composition. The invention provides application of guanidine compounds combined with piperlongumine in preparation of anti-cancer drugs. Wherein the guanidine compound can be selected from metformin. Compared with a single-dose drug, the combined drug provided by the invention has better anticancer activity. Compared with platinum chemotherapeutic drugs, the drug combination scheme has the same tumor killing efficacy, and has no obvious influence on mouse weight, immune system, liver function, kidney function and the like, which indicates that the toxic and side effects of the drug combination are obviously weaker than those of the platinum chemotherapeutic drugs. Therefore, the drug combination scheme provided by the invention has a very good application prospect.

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

The invention provides a low-dose transdermal patch with high drug release, and relates to the technical field of transdermal patches. The low-dose transdermal patch with high drug release comprises a backing layer, an intelligent response type pressure-sensitive adhesive storage layer and an anti-sticking layer, and the intelligent response type pressure-sensitive adhesive storage layer is composed of an upper quick release adjusting layer, a middle buffer transition layer and a lower slow release core layer; the upper quick-release adjusting layer contains a temperature-sensitive penetration promoting system and is composed of composite microspheres of menthol, borneol and polyoxyethylated castor oil, the surfaces of the composite microspheres are coated with poly (N-isopropylacrylamide) temperature-sensitive coatings, when the skin temperature is higher than 34 DEG C, the coatings swell to accelerate drug release, and the content of the coatings accounts for 5%-20% (w / w) of the total weight of the upper layer. And through an intelligent response mechanism, the low-dose drug effect is improved, the stimulation is reduced, various environments are adapted, the targeting property is enhanced, and the medication safety and applicability are improved.

The invention concerns improvements in needle-free devices for the delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free devices disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

This invention provides an atomization module for an atomizer, comprising a pressure-resistant solution chamber, a pressure assembly, a heating assembly, and a sealing nozzle. The pressure assembly is connected to the pressure-resistant solution chamber and can increase the pressure inside the chamber. The sealing nozzle is connected to an outlet on the pressure-resistant solution chamber and includes a transition section and a spray plate. The spray plate has an internally closed blind hole. The transition section, the blind hole, and the outlet are interconnected. The blind hole opens from the inside out after exceeding the pressure limit, and the liquid to be atomized is sprayed out from the blind hole. The inner diameters of the pressure-resistant solution chamber, the transition section, and the blind hole decrease sequentially. The heating assembly can heat the pressure-resistant solution chamber. The atomization module of this invention has a faster atomization rate, a larger capacity range for atomized solution per spray, and no special requirements on the device posture during atomization. It can deliver both micro-dose and large-dose drugs as needed, making it more widely applicable.

The invention discloses a sitagliptin phosphate pharmaceutical composition as well as a preparation, a preparation method and application thereof. The pharmaceutical composition comprises sitagliptin phosphate, HP-beta-CD and mesoporous silica. According to the invention, a synergistic effect is generated by utilizing a molecular-level clathration effect of HP-beta-CD and a nano-level confinement adsorption effect of mesoporous silica, so that chemical degradation of sitagliptin phosphate, especially generation of a genotoxic impurity NTTP, is remarkably inhibited from molecular and physical double levels, and the stability of a product is greatly improved. Meanwhile, the mesoporous silica effectively solves the technical problems that HP-beta-CD is strong in hygroscopicity and not easy to directly tablet, and the content uniformity of low-dose drugs is fundamentally ensured by forming uniform composite particles. The process is simple, granulation is not needed, the tablet is suitable for industrial production, the prepared tablet is excellent in stability and high in safety, and animal experiments show that the bioavailability of the tablet is superior to that of a commercially available reference preparation.

The invention discloses preparation of a mesoporous drug-loading system with a controllable aperture and application of the mesoporous drug-loading system in improvement of oral absorption of insoluble drugs, and belongs to the technical field of medicines. The drug loading system takes dendritic mesoporous silica as a carrier of an insoluble drug and fenofibrate as a model drug, is used for improving the physical stability and oral bioavailability of the insoluble drug, and is particularly suitable for clinical large-dose drugs. The dendritic mesoporous silica drug-loading system provided by the invention is superior to commercially available mesoporous auxiliary materials and traditional solid dispersion carrier materials in the aspects of improving the physical stability of the insoluble drug and enhancing the oral absorption effect, and provides important reference for the research of an oral preparation of the insoluble drug.

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

The embodiment of the invention provides an injector for injecting medicine with adjustable dosage, and belongs to the technical field of medical instruments. The trigger mechanism comprises a button and a knob which are clamped together; the adjusting mechanism comprises gear sets meshed together, one end of the adjusting mechanism is fixed to the injector shell and rotatably connected with the triggering mechanism, the other end of the adjusting mechanism is fixedly connected with the adjusting rod, and a torsional spring is arranged in the adjusting mechanism; the push mechanism comprises a push rod and a push part; one end of the push rod is fixedly connected with the button; the other end of the push rod is meshed with the gear set; one end of the push part is fixedly connected with the adjusting rod; the knob is rotated to drive the adjusting rod to rotate to a preset dosage position, and meanwhile the gear set rotates in an engaged mode to enable the torsional spring to store force. The button is pressed to drive the push rod to axially move towards the injection end, so that the gear set is separated, and the torsion spring force release adjusting rod rotates to push the pushing part to push quantitative medicine to complete injection. The injector can adjust and lock the dosage and then automatically inject.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a high-absorptivity, high-antioxidation and high-dose coenzyme Q10 orally disintegrating tablet and a preparation method thereof. The high-absorptivity, high-antioxidation and high-dose coenzyme Q10 orally disintegrating tablet is prepared from the following raw materials in parts by weight: 15 to 30 parts of coenzyme Q10, 5 to 10 parts of inclusion agent, 0.1 to 2 parts of flavoring agent, 60 to 80 parts of filling agent, 3 to 8 parts of disintegrating agent and 0.1 to 1 part of lubricating agent. The preparation method comprises the following steps: granulating and drying the flavoring agent and the filling agent, mixing the coenzyme Q10 with the inclusion agent, and finally mixing and tabletting with the disintegrating agent and the lubricant. The invention breaks through the limitation of high-dose drug loading, solves the sticking problem, accelerates disintegration and absorption, improves bioavailability and antioxidant activity, and has wide application market.

This utility model discloses a water treatment dosing device, including a base, an aeration pump on one side of the inner wall of the base, and an air supply pipe connected to the air outlet of the aeration pump. A drive motor is located on one side of the inner wall of the base, and a dosing tank is located at the center of the top of the base. An air injection pipe is located at the bottom of the inner wall of the dosing tank. One end of the air supply pipe is mounted on the top of the air injection pipe via a bearing, and the bottom end of the air injection pipe is fixedly connected to the output end of the drive motor via a flat key. Multiple stirring rods are welded to the outside of the air injection pipe, and multiple air holes are opened on the outside of the air injection pipe. When mixing aqueous solution and chemicals, the aeration pump is started, and the aeration pump injects air into the air injection pipe through the air supply pipe. The air is discharged through the air holes on the air injection pipe. The forced airflow will disturb the chemical particles, achieving full dispersion of the chemical particles. For active ingredients with poor solubility or easy separation, it can significantly improve the uniformity of low-dose drugs and reduce the risk of clumping of hygroscopic drugs due to uneven humidity.